19-4117539-T-G
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PS1_ModeratePM1PM2PM5PP3_ModeratePP5_Very_Strong
The NM_030662.4(MAP2K2):c.183A>C(p.Lys61Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely pathogenic in ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. K61E) has been classified as Likely pathogenic.
Frequency
Consequence
NM_030662.4 missense
Scores
Clinical Significance
Conservation
Publications
- cardiofaciocutaneous syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
- cardiofaciocutaneous syndrome 4Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, PanelApp Australia, Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- neurofibromatosis-Noonan syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Noonan syndromeInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_030662.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MAP2K2 | NM_030662.4 | MANE Select | c.183A>C | p.Lys61Asn | missense | Exon 2 of 11 | NP_109587.1 | ||
| MAP2K2 | NM_001440688.1 | c.183A>C | p.Lys61Asn | missense | Exon 2 of 9 | NP_001427617.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MAP2K2 | ENST00000262948.10 | TSL:1 MANE Select | c.183A>C | p.Lys61Asn | missense | Exon 2 of 11 | ENSP00000262948.4 | ||
| MAP2K2 | ENST00000394867.9 | TSL:5 | n.622A>C | non_coding_transcript_exon | Exon 1 of 10 | ||||
| MAP2K2 | ENST00000599345.1 | TSL:5 | n.380A>C | non_coding_transcript_exon | Exon 2 of 7 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 36
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Missense variants in this gene are often considered pathogenic (HGMD); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 32901917, 25370473, 22753777, 19156172, 26399658, 22177953, 29493581)
Cardiofaciocutaneous syndrome 4 Pathogenic:1
Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with supporting evidence (ClinVar ID: VCV000279998.2, PS1_P). The missense variant is located in a mutational hot spot and/or well-established functional domain in which established pathogenic variants have been reported (PM1). It is not observed in the gnomAD v2.1.1 dataset (PM2). A different missense change at the same codon (p.Lys61Glu) has been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000040769.5, PMID: 25326637, PM5). The variant was observed as assumed (i.e. paternity and maternity not confirmed) de novoo (3billion dataset, PM6). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.653, 3Cnet: 0.951, PP3). Patient's phenotype is considered compatible with Cardiofaciocutaneous syndrome 4 (3billion dataset, PP4).Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline.
RASopathy Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Lys61 amino acid residue in MAP2K2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 17366577, 24719372, 25326637). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MAP2K2 protein function. ClinVar contains an entry for this variant (Variation ID: 279998). This missense change has been observed in individual(s) with MAP2K2-related conditions (PMID: 32901917). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces lysine, which is basic and polar, with asparagine, which is neutral and polar, at codon 61 of the MAP2K2 protein (p.Lys61Asn).
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at